A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Trial Profile

A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Hepcidin (Primary)
  • Indications Haemochromatosis
  • Focus Pharmacodynamics
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 15 Jan 2018 New source identified and integrated (NCT03395704 ClinicalTrials.gov: US National Institutes of Health).
    • 22 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top